About Us
Our mission is to revolutionize disease treatment for patients by developing small molecule therapeutics that modify RNA expression.
Our Mindsets
RNA misexpression has been found to cause a growing list of diseases, from orphan and neurological conditions to major cancers. Very few treatments are available for these challenging conditions, many of which have been considered “undruggable.”
Leadership
Skyhawk’s leadership has deep expertise in RNA splicing and structure, neurology, and Huntington’s Disease, as well as computational biology, machine learning, and drug development.
Lorem Ipsum
Nonsenderem reicabore sum quis dusaestint Iqui offictate pa quos ni cus quid et pre nonsenderem reicabore sum quis dusaestint.
Our Locations
We began as a global company, with founding labs in Basel, Switzerland and Boston, Massachusetts.
